BioWorld

May 25, 2010

Biogen and Abbott Start Phase III Trial of MS Antibody Daclizumab

Biogen Idec Inc. and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis. (BioWorld Today) Read More

NormOxys Gets $17.5M Series B to Fund Cardio, Cancer Studies

'Vino' What All Start-ups Want: Fated Partners Linking at C21

NewCo News: Immunome Harnessing Immune System's Natural Curative Ability

Corrections & Clarifications

Other News To Note

Stock Movers

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...